Comparing Enoxaparin and Unfractionated Heparin for Thromboprophylaxis
Author Information
Author(s): McGarry Lisa J, Stokes Michael E, Thompson David
Primary Institution: Health Economics & Outcomes Research, i3 Innovus
Hypothesis
Is enoxaparin more effective than unfractionated heparin in preventing venous thromboembolism in acutely-ill medical inpatients?
Conclusion
Enoxaparin significantly reduces the risk of venous thromboembolism compared to unfractionated heparin without differences in side effects or costs.
Supporting Evidence
- Enoxaparin patients had a 1.7% incidence of VTE compared to 6.3% in UFH patients.
- The risk of DVT was significantly lower in the enoxaparin group.
- Side effects and hospital costs were similar between the two groups.
Takeaway
This study found that giving enoxaparin instead of unfractionated heparin helps prevent blood clots in sick patients, making it a better choice.
Methodology
The study analyzed data from a large US hospital database, comparing outcomes of patients receiving either enoxaparin or unfractionated heparin for thromboprophylaxis.
Potential Biases
Potential confounding factors due to non-random assignment of patients to treatment groups.
Limitations
The study is limited by its retrospective design and reliance on administrative data, which may contain inaccuracies.
Participant Demographics
Patients were aged 40 years and older, with a higher proportion of females and whites in the enoxaparin group.
Statistical Information
P-Value
p<0.001
Confidence Interval
0.13, 0.53
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website